Literature DB >> 33222122

Effects of growth hormone on cognitive, motor, and behavioral development in Prader-Willi syndrome children: a meta-analysis of randomized controlled trials.

Yunyun Luo1, Zhoude Zheng2, Yingying Yang1, Xi Bai1, Hongbo Yang1, Huijuan Zhu1, Hui Pan3, Shi Chen4.   

Abstract

PURPOSE: The benefits of growth hormone (GH) therapy in Prader-Willi syndrome (PWS) children are well established, but there is still considerable controversy regarding whether GH treatment can improve cognitive, motor, and behavioral development in PWS children. The objectives of this meta-analysis were to quantitatively evaluate the effects of GH on cognitive, motor function, and behavioral development in PWS children.
METHODS: Randomized controlled trials (RCTs) examining the effects of GH on cognitive, motor, and behavioral development in PWS children were identified by searching the MEDLINE, EMBASE, and Cochrane Library databases. Intervention effects were represented by Hedges'g and pooled to calculate effect sizes using a random-effects model.
RESULTS: Ten relevant studies comprising data from 302 participants were finally included. We observed no significant difference in cognitive performance between the GH treatment group and the control group (p = 0.197). GH treatment was shown to remarkably improve motor development in PWS children compared with the control treatment (p < 0.001), with moderate positive treatment effects (Hedges'g [95% CI] = 0.71 [0.38, 1.03]). There were no significant differences between the GH group and the control group based on objective assessments of behavioral development (p = 0.53).
CONCLUSIONS: The meta-analysis suggested that GH treatment had a significantly positive effect on motor development, with moderate treatment effects in PWS children; however, there was no evidence of effects on cognitive or behavioral development.

Entities:  

Keywords:  Growth hormone (GH); Prader-Willi syndrome (PWS); behavior; cognition; motor

Mesh:

Substances:

Year:  2020        PMID: 33222122     DOI: 10.1007/s12020-020-02547-3

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  1 in total

1.  Impact of genetic subtypes of Prader-Willi syndrome with growth hormone therapy on intelligence and body mass index.

Authors:  Merlin G Butler; Naomi A Matthews; Nidhi Patel; Abhilasha Surampalli; June-Anne Gold; Manaswitha Khare; Travis Thompson; Suzanne B Cassidy; Virginia E Kimonis
Journal:  Am J Med Genet A       Date:  2019-07-16       Impact factor: 2.802

  1 in total
  4 in total

1.  Molecular Classes and Growth Hormone Treatment Effects on Behavior and Emotion in Patients with Prader-Willi Syndrome.

Authors:  Ranim Mahmoud; Heidi D Swanson; Merlin G Butler; Pamela Flodman; June-Anne Gold; Jennifer L Miller; Elizabeth Roof; Kathryn Osann; Elisabeth Dykens; Daniel J Driscoll; Virginia Kimonis
Journal:  J Clin Med       Date:  2022-05-04       Impact factor: 4.964

2.  Correlation of Genotype and Perinatal Period, Time of Diagnosis and Anthropometric Data before Commencement of Recombinant Human Growth Hormone Treatment in Polish Patients with Prader-Willi Syndrome.

Authors:  Agnieszka Lecka-Ambroziak; Marta Wysocka-Mincewicz; Katarzyna Doleżal-Ołtarzewska; Agata Zygmunt-Górska; Teresa Żak; Anna Noczyńska; Dorota Birkholz-Walerzak; Renata Stawerska; Maciej Hilczer; Monika Obara-Moszyńska; Barbara Rabska-Pietrzak; Elżbieta Gołębiowska; Adam Dudek; Elżbieta Petriczko; Mieczysław Szalecki
Journal:  Diagnostics (Basel)       Date:  2021-04-28

3.  Incidence of death from kidney diseases among cancer patients: a US population-based analysis.

Authors:  Xiaoli Li; Wenhui Chen; Jinfang Feng; Bo Zhao
Journal:  Int Urol Nephrol       Date:  2021-03-08       Impact factor: 2.370

4.  Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader-Willi Syndrome Patients: A Cohort Study.

Authors:  Aitana Ayet-Roger; Lorena Joga-Elvira; Assumpta Caixàs; Raquel Corripio
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.